- Home
- CANF vs MYSZ Comparison
CANF vs MYSZ Comparison
Compare CANF & MYSZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- MYSZ
- Stock Information
- Founded
- CANF 1994
- MYSZ 1999
- Country
- CANF Israel
- MYSZ Israel
- Employees
- CANF N/A
- MYSZ N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- MYSZ Computer Software: Prepackaged Software
- Sector
- CANF Health Care
- MYSZ Technology
- Exchange
- CANF Nasdaq
- MYSZ Nasdaq
- Market Cap
- CANF 9.4M
- MYSZ 8.2M
- IPO Year
- CANF N/A
- MYSZ N/A
- Fundamental
- Price
- CANF $1.54
- MYSZ $2.07
- Analyst Decision
- CANF Strong Buy
- MYSZ Strong Buy
- Analyst Count
- CANF 2
- MYSZ 1
- Target Price
- CANF $14.00
- MYSZ $3.00
- AVG Volume (30 Days)
- CANF 117.2K
- MYSZ 8.2M
- Earning Date
- CANF 02-03-2025
- MYSZ 11-14-2024
- Dividend Yield
- CANF N/A
- MYSZ N/A
- EPS Growth
- CANF N/A
- MYSZ N/A
- EPS
- CANF N/A
- MYSZ N/A
- Revenue
- CANF $667,000.00
- MYSZ $9,632,000.00
- Revenue This Year
- CANF $409.56
- MYSZ $35.62
- Revenue Next Year
- CANF N/A
- MYSZ $12.88
- P/E Ratio
- CANF N/A
- MYSZ N/A
- Revenue Growth
- CANF N/A
- MYSZ 43.89
- 52 Week Low
- CANF $1.29
- MYSZ $1.05
- 52 Week High
- CANF $4.69
- MYSZ $9.40
- Technical
- Relative Strength Index (RSI)
- CANF 42.93
- MYSZ 42.86
- Support Level
- CANF $1.55
- MYSZ $2.24
- Resistance Level
- CANF $1.64
- MYSZ $3.15
- Average True Range (ATR)
- CANF 0.10
- MYSZ 0.55
- MACD
- CANF 0.01
- MYSZ -0.21
- Stochastic Oscillator
- CANF 11.76
- MYSZ 1.35
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About MYSZ My Size Inc.
My Size Inc is a USA based technology company that focuses on the development of an application that assists the consumer to accurately take the measurements of his or her own body to fit clothing without the need to try them on using a smartphone. The purpose of the company's business is to simplify the process of clothing acquisition through the Internet and to significantly reduce the rate of returns of clothing which were acquired through the internet and which are returned to the stores because of ill-fitting. The company generates its revenue through selling products to customers, and licensing cloud-enabled software subscriptions, associated software maintenance and support.